Technical Analysis for TRVI - Trevi Therapeutics, Inc.

Grade Last Price % Change Price Change
F 2.43 -2.61% -0.07
TRVI closed down 2.61 percent on Thursday, April 15, 2021, on 21 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical TRVI trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -2.61%
NR7 Range Contraction -2.61%
Lower Bollinger Band Walk Weakness -2.61%
Stochastic Reached Oversold Weakness -2.61%
Oversold Stochastic Weakness -2.61%
Older End-of-Day Signals for TRVI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 20 hours ago
60 Minute Opening Range Breakdown about 21 hours ago
Down 2 % about 21 hours ago
Down 1% about 21 hours ago
Fell Below Lower Bollinger Band about 21 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Trevi Therapeutics, Inc. Description

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Chemical Compounds Organic Compounds Opioid Analgesics Ethers Idiopathic Pulmonary Fibrosis Morphinans Pulmonary Fibrosis Cough Physiology Phenols Parkinson’s Disease Pruritus Dyskinesia Nervous Systems Opioid Receptors Peripheral Nervous System Chronic Cough Levodopa Induced Dyskinesia Prurigo Prurigo Nodularis

Is TRVI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.5
52 Week Low 2.13
Average Volume 91,538
200-Day Moving Average 3.60
50-Day Moving Average 2.85
20-Day Moving Average 2.70
10-Day Moving Average 2.63
Average True Range 0.18
ADX 21.13
+DI 13.61
-DI 24.96
Chandelier Exit (Long, 3 ATRs ) 2.42
Chandelier Exit (Short, 3 ATRs ) 2.94
Upper Bollinger Band 2.96
Lower Bollinger Band 2.44
Percent B (%b) -0.01
BandWidth 19.42
MACD Line -0.08
MACD Signal Line -0.05
MACD Histogram -0.0233
Fundamentals Value
Market Cap 44.67 Million
Num Shares 18.4 Million
EPS -9.14
Price-to-Earnings (P/E) Ratio -0.27
Price-to-Sales 0.00
Price-to-Book 1.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.57
Resistance 3 (R3) 2.57 2.54 2.54
Resistance 2 (R2) 2.54 2.50 2.53 2.53
Resistance 1 (R1) 2.48 2.48 2.47 2.48 2.53
Pivot Point 2.45 2.45 2.44 2.44 2.45
Support 1 (S1) 2.39 2.41 2.38 2.39 2.33
Support 2 (S2) 2.36 2.39 2.35 2.33
Support 3 (S3) 2.30 2.36 2.32
Support 4 (S4) 2.30